Mouse model of neonatal fungal colonization to study homeostasis and disease
- Institution
- LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER, CA
- Principal investigator
- Marc Swidergall
- Funding
- $245K
- Duration
- 2025–2027
Moonbase score
Still being scored
Abstract
SUMMARY While the fungus Candida albicans has largely been studied as a pathogen, its primary lifestyle is as a commensal on mucosal surfaces, including the oral cavity. Microorganisms that occupy mucosal surfaces are critical for appropriately tuning immune responses to ensure efficient responses to invading pathogens while limiting responses directed towards host tissues. In this context, commensal fungi play important roles in host immunity and inflammation. For instance, C. albicans colonization induces cross-reactive T cells and innate memory in immune cells, a mechanism termed trained immunity. Accumulating evidence from our group and others have convincingly demonstrated that oral commensal colonization with C. albicans induces specific immune responses, therefore contributing to mucosal immune system plasticity. However, our knowledge of antifungal immunity is based on data of adult animals. Importantly, humans are colonized with C. albicans during birth. Furthermore, the neonatal immune system has long been regarded immature when compared to the adult immune system. However, is becomes clear that neonatal immunity is specifically adapted to prevent pathogen invasion, while supported its development. However, the fundamental immunological consequences of C. albicans colonization in neonates are still unknown. We developed a novel mouse model of commensal Candida colonization in neonates. This proposal will characterize oral mucosal immune cell populations in neonates in response to commensal Candida colonization (Aim 1) and elucidate age related differences in IL- 17 and IL-22 immunity during oral fungal colonization (Aim 2).
LOADING MOONBASE SCORE
Questions for LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER
Answered by the team behind this research.
No questions yet. Sign in to ask the first one
Related grants
Same researchers, same institution, same topic, scored first.
- NIH · Lundquist Institute for Biomedical Innovation at Harbor-Ucla Medical CenterNot yet scored
Oral commensal fungi and structural immunity
Marc Swidergall · $508K · 2022–2027
- NIH · Lundquist Institute for Biomedical Innovation at Harbor-Ucla Medical CenterNot yet scored
Deciphering Immunopathogenesis of MUCORmycosis to ADVANCE Risk stratification, Diagnosis and Management of the Disease
Ashraf S. Ibrahim · $2.2M · 2025–2030
- NIH · Lundquist Institute for Biomedical Innovation at Harbor-Ucla Medical CenterNot yet scored
Administrative Core
Ashraf S. Ibrahim · $132K · 2025–2030